The Negative Impact of Sarcopenia on Hepatocellular Carcinoma Treatment Outcomes
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Sarcopenia, a loss of muscle mass, negatively impacts outcomes for hepatocellular carcinoma (HCC) patients across all treatments. Early detection and interventions to restore muscle mass are crucial for improving survival and treatment response in HCC.
Area Of Science
- Hepatology
- Oncology
- Geriatrics
Background
- Hepatocellular carcinoma (HCC) is a significant global health issue with complex etiological factors and treatment modalities.
- Sarcopenia, defined as loss of skeletal muscle mass, strength, and function, is increasingly recognized as a critical prognostic factor in HCC.
- This review focuses on the impact of sarcopenia on outcomes for HCC patients undergoing liver transplantation, surgical resection, locoregional treatments, and systemic therapies.
Purpose Of The Study
- To systematically review and analyze the existing literature on the association between sarcopenia and treatment outcomes in hepatocellular carcinoma (HCC).
- To elucidate the role of sarcopenia as a prognostic indicator across diverse HCC treatment strategies.
- To highlight the need for personalized management approaches considering sarcopenia in HCC patients.
Main Methods
- A comprehensive literature search was performed using peer-reviewed articles.
- The search focused on studies investigating sarcopenia and treatment outcomes in HCC patients.
- Data were collected from inception up to October 2023.
Main Results
- Sarcopenia is prevalent in HCC patients, with varying reported frequencies due to differing diagnostic criteria.
- Sarcopenia independently correlates with poorer overall survival (OS), recurrence-free survival (RFS), and progression-free survival (PFS) across all major HCC treatment modalities.
- Sarcopenia is associated with increased adverse events, particularly with tyrosine-kinase inhibitors (TKIs) and surgical interventions, and larger tumor size at diagnosis. Post-treatment muscle mass decline is a key determinant of reduced OS.
Conclusions
- Sarcopenia, whether pre-existing or developing post-treatment, adversely affects HCC treatment response and survival across all therapeutic strategies.
- Evaluating sarcopenia before treatment initiation is essential for patient prognostication and tailoring treatment approaches.
- Further research is needed to explore the impact of sarcopenia on HCC recurrence and extrahepatic spread, and to investigate therapies, such as supervised physical activity, to restore muscle mass and improve OS.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...